NDAORALTABLET
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
HEMADY (dexamethasone) by Bridge Therapeutics is corticosteroid hormone receptor agonists [moa]. Approved for multiple myeloma, diabetic macular edema. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMADY is an oral corticosteroid tablet containing dexamethasone, a corticosteroid hormone receptor agonist approved in 2019. It is indicated for multiple hematologic malignancies (multiple myeloma, lymphoma, acute leukemia), solid tumors, and non-oncologic conditions including diabetic macular edema, sudden sensorineural hearing loss, and postoperative nausea/vomiting. Dexamethasone works by binding glucocorticoid receptors to suppress immune responses and reduce inflammation.
$0.159MPart D
Peak11.6 years to LOEHEMADY is at peak lifecycle with minimal Part D spending ($159K in 2023), suggesting a niche positioning or limited commercial scale relative to blockbuster competitors; the small team likely focuses on specialty/oncology segments.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (2)
Clinical Trials (20)
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Started May 2026
50 enrolled
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Started May 2026
380 enrolled
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started May 2026
500 enrolled
Multiple Myeloma
Worked on HEMADY at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.